Bile Duct Cancer (Cholangiocarcinoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 2359 Published: December 30, 2021 Report Code: GMDGDHC13209IDB

Bile Duct Cancer (Cholangiocarcinoma) pipeline market research report provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects.

What are the key targets in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market?

The key targets in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market are Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, Fibroblast Growth Factor Receptor 2, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 3, Vascular Endothelial Growth Factor Receptor 2, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, and DNA. Programmed Cell Death 1 Ligand 1 has the highest number of pipeline products.

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by targets

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by targets

For more target insights, download a free report sample

What are the key MoA in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market?

The key MoA in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market are Programmed Cell Death 1 Ligand 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Fibroblast Growth Factor Receptor 2 Inhibitor, Fibroblast Growth Factor Receptor 1 Inhibitor, Fibroblast Growth Factor Receptor 3 Inhibitor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, DNA Synthesis Inhibitor, Tubulin Inhibitor, and Vascular Endothelial Growth Factor Receptor 3 Inhibitor. Programmed Cell Death 1 Ligand 1 Inhibitor has the highest number of pipeline products.

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by MoA

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by MoA

For more MoA insights, download a free report sample

What are the key RoA in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market?

The key RoA in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market are Intravenous, Oral, Subcutaneous, Parenteral, Intravenous Drip, Intratumor, Intradermal, Intraperitoneal, Intravesical, Inhalational, and Intraarterial. Intravenous has the highest number of pipeline products.

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by RoA

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by RoA

For more RoA insights, download a free report sample

What are the key molecule types in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market?

The key molecule types in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market are Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Cell Therapy, Fusion Protein, Antisense RNAi Oligonucleotide, Oncolytic Virus, Biologic, and Oligonucleotide. Small Molecule has the highest number of pipeline products.

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by molecule type

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by molecule type

For more molecule type insights, download a free report sample

Which are the key companies in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market?

The key companies in the Bile Duct Cancer (Cholangiocarcinoma) pipeline market are AstraZeneca Plc, Eli Lilly and Co, Bayer AG, Jiangsu Hengrui Medicine Co Ltd, Alphamab Oncology, Hutchison MediPharma Ltd, Merck & Co Inc, BeiGene Ltd, Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, and Advenchen Laboratories LLC. AstraZeneca Plc has the highest number of pipeline products.

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by companies

Bile Duct Cancer (Cholangiocarcinoma) pipeline market, by companies

To know more about key companies, download a free report sample

Market report overview

Key targets Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, Fibroblast Growth Factor Receptor 2, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 3, Vascular Endothelial Growth Factor Receptor 2, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, and DNA
Key MoA Programmed Cell Death 1 Ligand 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Fibroblast Growth Factor Receptor 2 Inhibitor, Fibroblast Growth Factor Receptor 1 Inhibitor, Fibroblast Growth Factor Receptor 3 Inhibitor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, DNA Synthesis Inhibitor, Tubulin Inhibitor, and Vascular Endothelial Growth Factor Receptor 3 Inhibitor
Key RoA Intravenous, Oral, Subcutaneous, Parenteral, Intravenous Drip, Intratumor, Intradermal, Intraperitoneal, Intravesical, Inhalational, and Intraarterial
Key molecule types Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Cell Therapy, Fusion Protein, Antisense RNAi Oligonucleotide, Oncolytic Virus, Biologic, and Oligonucleotide
Key companies AstraZeneca Plc, Eli Lilly and Co, Bayer AG, Jiangsu Hengrui Medicine Co Ltd, Alphamab Oncology, Hutchison MediPharma Ltd, Merck & Co Inc, BeiGene Ltd, Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, and Advenchen Laboratories LLC

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma)
  • The report reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Bile Duct Cancer (Cholangiocarcinoma) therapeutics and enlists all their major and minor projects
  • The report assesses Bile Duct Cancer (Cholangiocarcinoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma)

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Key Players

  • AbbVie Inc

    Ability Pharmaceuticals SL

    ABL Bio Inc

    ABM Therapeutics Inc

    ADC Therapeutics SA

    Advenchen Laboratories LLC

    Affimed GmbH

    Akeso Inc

    Alentis Therapeutics AG

    Alphamab Oncology

    Ambrx Biopharma Inc

    Andes Biotechnologies

    AngioGenex Inc

    Apexigen Inc

    Apollomics Inc

    Arbele Ltd

    Ascelia Pharma AB

    Aslan Pharmaceuticals Ltd

    AstraZeneca Plc

    Bavarian Nordic A/S

    Bayer AG

    BeiGene Ltd

    Beijing Biostar Technologies Ltd

    Beijing Combio Pharmaceuticals Ltd

    Beijing Immunochina Pharmaceuticals Co Ltd

    Beijing Scitech-MQ Pharmaceuticals Ltd

    Betta Pharmaceuticals Co Ltd

    Biocad

    BioMed Valley Discoveries Inc

    BioNTech SE

    Biotheus Inc

    BJ Bioscience Inc

    Blueprint Medicines Corp

    Boehringer Ingelheim International GmbH

    Bold Therapeutics Inc

    BridgeBio Pharma Inc

    Bristol-Myers Squibb Co

    Calithera Biosciences Inc

    CanBas Co Ltd

    Cantargia AB

    Celldex Therapeutics Inc

    Cellestia Biotech AG

    Celltrion Inc

    Celon Pharma SA

    Chineo Med Beijing Co Ltd

    Chong Kun Dang Pharmaceutical Corp

    Clovis Oncology Inc

    Coherent Biopharma

    Convalife

    Corcept Therapeutics Inc

    CSPC Pharmaceutical Group Ltd

    CStone Pharmaceuticals Co Ltd

    Curegenix Inc

    Cyclacel Pharmaceuticals Inc

    CytomX Therapeutics Inc

    Daiichi Sankyo Co Ltd

    Debiopharm International SA

    Delcath Systems Inc

    Delta-Fly Pharma Inc

    Eddingpharm Inc

    Eisai Co Ltd

    Eli Lilly and Co

    Elucida Oncology Inc

    Exelixis Inc

    F. Hoffmann-La Roche Ltd

    Faron Pharmaceuticals Oy

    Forma Therapeutics Inc

    Fujifilm Holdings Corp

    FUJIFILM Toyama Chemical Co Ltd

    Genenta Science srl

    Genexine Inc

    GenFleet Therapeutics (Shanghai) Inc

    GenoImmune Therapeutics Biotechnology Co Ltd

    Genoscience Pharma

    GI Innovation Co Ltd

    GlaxoSmithKline Plc

    GO Therapeutics Inc

    Gracell Biotechnologies Inc

    Guangdong Zhongsheng Pharmaceutical Co Ltd

    H3 Biomedicine Inc

    Hainan Kaibo Biotechnology Co Ltd

    Harbin Gloria Pharmaceuticals Co Ltd

    Heidelberg Pharma AG

    Huabo Biopharm (Shanghai) Co Ltd

    Huahui Anjian (Beijing) Biotechnology Co Ltd

    Hutchison MediPharma Ltd

    ImCare Biotech LLC

    Immix BioPharma Inc

    ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd

    Immunitor Inc

    Incyte Corp

    Inmune Bio Inc

    InnoCare Pharma Ltd

    Innopharmax Inc

    Innovent Biologics Inc

    Inspirna Inc

    Intensity Therapeutics Inc

    Ipsen SA

    J-Pharma Co Ltd

    Jiangsu Hengrui Medicine Co Ltd

    Johnson & Johnson

    Kangen Pharmaceuticals Co Ltd

    Kinnate Biopharma Inc

    Komipharm International Co Ltd

    KPC Pharmaceuticals Inc

    Kyowa Kirin Co Ltd

    LaNova Medicines Ltd

    Leap Therapeutics Inc

    Les Laboratoires Servier SAS

    Ligand Pharmaceuticals Inc

    LipoMedix Pharmaceutical Inc

    Lokon Pharma AB

    Luzitin SA

    MacroGenics Inc

    Medicenna Therapeutics Corp

    MediciNova Inc

    Medivir AB

    Merck & Co Inc

    Merck KGaA

    Merus NV

    Mina Therapeutics Ltd

    Mirati Therapeutics Inc

    Molecular Templates Inc

    Mundipharma EDO GmbH

    NanoCarrier Co Ltd

    Netherlands Translational Research Center BV

    Newish Technology Beijing Co Ltd

    NGM Biopharmaceuticals Inc

    Nkarta Inc

    Northwest Biotherapeutics Inc

    Novartis AG

    NuCana Plc

    Oasmia Pharmaceutical AB

    Oncocross Co Ltd

    Ono Pharmaceutical Co Ltd

    Orgenesis Inc

    PCI Biotech Holding ASA

    Pfizer Inc

    Pharma Mar SA

    Pharmaxis Ltd

    Phosplatin Therapeutics LLC

    Pieris Pharmaceuticals Inc

    Provecs Medical GmbH

    Puma Biotechnology Inc

    Puretech Health Plc

    Quadriga BioSciences Inc

    Rafael Pharmaceuticals Inc

    RedHill Biopharma Ltd

    Redx Pharma Plc

    Relay Therapeutics Inc

    RemeGen Co Ltd

    Rhizen Pharmaceuticals SA

    Samyang Biopharmaceuticals Corp

    Sanofi

    Seagen Inc

    Seald AS

    Senhwa Biosciences Inc

    Shandong Boan Biotechnology Co Ltd

    Shanghai Cell Therapy Group Co

    Shanghai De Novo Pharmatech Co Ltd

    Shanghai Haihe Biopharma Co Ltd

    Shanghai Haishi Biopharmaceutical Co Ltd

    Shanghai Junshi Bioscience Co Ltd

    Shanghai Miracogen Inc

    Shanghai Novamab Biopharmaceuticals Co Ltd

    Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd

    Shenghe (China) Biopharmaceutical Co Ltd

    Shouyao Holding Co Ltd

    Sichuan Kelun Pharmaceutical Co Ltd

    Sillajen Biotherapeutics

    Silverback Therapeutics Inc

    Sirnaomics Inc

    SMT bio Co Ltd

    Sorrento Therapeutics Inc

    Sotio AS

    SparkBioPharma Inc

    Starpharma Holdings Ltd

    Sun Pharma Advanced Research Company Ltd

    SupremeCure Pharma Inc

    Suzhou Hitebio Biotechnology Co Ltd

    Suzhou Zelgen Biopharmaceutical Co Ltd

    Symphogen A/S

    SynCore Biotechnology Co Ltd

    SyntheX Inc

    Taiho Oncology Inc

    Taiho Pharmaceutical Co Ltd

    Takeda Pharmaceutical Co Ltd

    Tango Therapeutics Inc

    TCR2 Therapeutics Inc

    tella Inc

    Tempest Therapeutics Inc

    TerSera Therapeutics LLC

    Therillia Development Co Inc

    Toray Industries Inc

    TOT Biopharm Co Ltd

    Transcenta Holding Ltd

    TransThera Sciences (Nanjing) Inc

    Tyra Biosciences Inc

    VasGene Therapeutics Inc

    Virogin Biotech Ltd

    Waterstone Hanxbio Pty Ltd

    WellMarker Bio Co Ltd

    Xencor Inc

    Yantai Rongchang Pharmaceutical Co Ltd

    Zhangzhou Pien Tze Huang Pharmaceutical Co Ltd

    Zhejiang Borui Biopharmaceutical Co Ltd

    ZielBio Inc

    Zymeworks Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bile Duct Cancer (Cholangiocarcinoma) – Overview

Bile Duct Cancer (Cholangiocarcinoma) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bile Duct Cancer (Cholangiocarcinoma) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bile Duct Cancer (Cholangiocarcinoma) – Companies Involved in Therapeutics Development

Bile Duct Cancer (Cholangiocarcinoma) – Drug Profiles

Bile Duct Cancer (Cholangiocarcinoma) – Dormant Projects

Bile Duct Cancer (Cholangiocarcinoma) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Bile Duct Cancer (Cholangiocarcinoma) – Dormant Projects, 2021

Bile Duct Cancer (Cholangiocarcinoma) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

Frequently Asked Questions

$2500

Can be used by individual purchaser only

$7500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.